Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immunotherapies in HIV-1 infection

Immunotherapies in HIV-1 infection Sarah L. Pett Faculty of Medicine, National Centre in HIV Purpose of review Epidemiology and Clinical Research, University of New The purpose of this review is to describe the current status of immunotherapies for the South Wales, Darlinghurst, New South Wales, Australia treatment of HIV-1 infection. This review is timely, as the results of the phase III Correspondence to Dr Sarah L. Pett, MRCP, FRACP, clinical trials of recombinant interleukin-2 (rIL-2) as adjuncts to combination antiretroviral Faculty of Medicine, National Centre in HIV Epidemiology and Clinical Research, University of New therapy are about to be released. South Wales, Darlinghurst, NSW 2010, Australia Recent findings Tel: +61 2 9385 0900; fax: +61 2 9385 0910; e-mail: spett@nchecr.unsw.edu.au For many years, the use of rIL-2 in HIV-infected individuals has been explored. Although the results of the clinical endpoint studies of rIL-2 are awaited, there are now further data Current Opinion in HIV and AIDS 2009, 4:188–193 for rIL-2 as a stand-alone therapy for the treatment of HIV. Maraviroc, a recently approved anti-HIV agent, is a small molecule antagonist of human chemokine receptor- 5. The recent observation that maraviroc-treated patients achieved higher CD4 and CD8 T-cell counts compared with comparator regimens (without http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Immunotherapies in HIV-1 infection

Current Opinion in HIV and Aids , Volume 4 (3) – May 1, 2009

Loading next page...
 
/lp/wolters-kluwer-health/immunotherapies-in-hiv-1-infection-4I5VfZ6Yde

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e328329d090
pmid
19532049
Publisher site
See Article on Publisher Site

Abstract

Sarah L. Pett Faculty of Medicine, National Centre in HIV Purpose of review Epidemiology and Clinical Research, University of New The purpose of this review is to describe the current status of immunotherapies for the South Wales, Darlinghurst, New South Wales, Australia treatment of HIV-1 infection. This review is timely, as the results of the phase III Correspondence to Dr Sarah L. Pett, MRCP, FRACP, clinical trials of recombinant interleukin-2 (rIL-2) as adjuncts to combination antiretroviral Faculty of Medicine, National Centre in HIV Epidemiology and Clinical Research, University of New therapy are about to be released. South Wales, Darlinghurst, NSW 2010, Australia Recent findings Tel: +61 2 9385 0900; fax: +61 2 9385 0910; e-mail: spett@nchecr.unsw.edu.au For many years, the use of rIL-2 in HIV-infected individuals has been explored. Although the results of the clinical endpoint studies of rIL-2 are awaited, there are now further data Current Opinion in HIV and AIDS 2009, 4:188–193 for rIL-2 as a stand-alone therapy for the treatment of HIV. Maraviroc, a recently approved anti-HIV agent, is a small molecule antagonist of human chemokine receptor- 5. The recent observation that maraviroc-treated patients achieved higher CD4 and CD8 T-cell counts compared with comparator regimens (without

Journal

Current Opinion in HIV and AidsWolters Kluwer Health

Published: May 1, 2009

There are no references for this article.